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A three-dimensional model for the ATP-binding site of the oncogene product v-src is proposed by the use 
of interactive computer graphics. A similar model would apply to sequence related proteins such as other 
oncogene products, the epidermal growth factor receptor, CAMP-dependent protein kinase and the cell divi- 
sion control protein CDC28. The model was proposed on the basis of the conservation of certain key resi- 
dues between the oncogene product family of proteins and several nucleotide binding proteins of known 
structures. 
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1. INTRODUCTION 
Questions about the relationship between nor- 
mal and cancerous cell growth are raised by the 
similarity of amino acid sequence between several 
oncogene products, such as v-src and v-erb-B, and 
a variety of other proteins - the epidermal growth 
space factor receptor (EGF-R), mammalian 
CAMP-dependent protein kinase (CAMP-K) and a 
cell division control protein CDC28 [l-lo]. 
Beyond just a sequence similarity many, but not 
all, of these oncogene products share a tyrosine 
phosphokinase activity with the EGF-R hnd a 
more general kinase activity with CAMP-K and 
CDC28. As a step towards understanding the rela- 
tionship between similarity in primary structure 
and kinase activity, we present a three-dimensional 
model for the ATP-binding site of the onsogene 
product v-src. A similar model would be applicable 
to all the above proteins and is consistent with ex- 
perimental evidence on the ATP binding site of 
CAMP-K [ 12,131. The proposal for the model was 
based on the conservation of certain key residues 
between the oncogene products and several 
nucleotide binding proteins [15-201 of known se- 
quence and three-dimensional structure (cf. [21]). 
2. MATERIALS AND METHODS 
+ To whom correspondence should be addressed 
Table 1 gives the sequence alignment of five 
nucleotide binding regions from five proteins of 
known sequence and structure. This set will be 
referred to as the ‘known structures’ and consists 
of the NAD-binding regions of glyceraldehyde-3- 
phosphate dehydrogenase (GPDH), lactate dehy- 
drogenase and alcohol dehydrogenase and the 
FAD-binding regions of glutathione reductase and 
p-hydroxybenzote hydroxylase. For reference the 
sequence numbering of GPDH will be used. This 
alignment and the observations about the role of 
conserved residues have been noted by other 
workers [32-331. Each binding region comprises 
two sections. The first consists of a &strand-cu- 
helix-&strand unit where the two strands (called 1 
and 2) lie parallel and adjacent. The second section 
consists of a &?-strand (called 3) and a few subse- 
quent residues. ,&Strand 3 lies parallel and adja- 
cent to 1 to give the strand order 312. The major 
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feature of the first section is the presence of the se- 
quence pattern Gly-X-Gly-X-X-Gly (Gly is G in 
table 1, X is any residue) in the region between the 
end of the &strand 1 and the start of the connec- 
ting a-helix. These glycines are essential for the 
binding of the ribose moiety and for the formation 
of the tight turn between the ,&strand and the (Y- 
helix (see legend to table 1). Another important 
feature is the presence of a conserved acidic side 
chain (Asp(D) or Glu(E)) at the carboxyl end of @- 
strand 2 (position 32). This side chain forms a 
hydrogen bond with the 2’ -hydroxyl of the 
adenine ribose. In the second section there is a con- 
served Gly at the end of &strand 3 whose struc- 
tural and functional role is not clear. 
Table 1 also gives a sequence alignment of two 
sections of several oncogene products, the EGF-R, 
CAMP-K and CDC28 and similar alignments have 
been published previously [l-l 11. All these se- 
quences will be referred to ‘oncogene’ sequences 
and their similarity implies that all the chains will 
adopt similar three-dimensional structures. We 
report how sections of the ‘oncogene’ sequences 
can be aligned with the ‘known structures’ and 
hence a three-dimensional model proposed. In the 
first section all the ‘oncogene’ sequences hare a 
common Gly-X-Gly-X-X-Gly which we have 
aligned with three Gly of the ‘known structures’. 
Some 17 to 23 residues beyond the third Gly there 
is an invariant Lys(K) in the ‘oncogenes’ which we 
have aligned with the conserved acidic residue of 
the ‘known structures’. In this alignment positions 
29 and 30 are always occupied by a hydrophobic 
side chain or by a neutral Gly. The second section 
of the ‘oncogene’ sequences includes the region 
before the tyrosine that in many of these proteins 
has been identified as the site of phosphorylation. 
Of interest is the presence of the conserved se- 
quence Asp-Phe-Gly (DFG) whose total conserva- 
tion is suggestive of a functional role. A secondary 
structure prediction for this region by the 
algorithm of Taylor and Thornton $3,241 shows 
that in most of the ‘oncogene’ sequences the 
residues before the Asp-Phe-Gly are predicted to 
adopt a p-strand conformation. Accordingly we 
have aligned the invariant Gly of the ‘oncogenes’ 
with the Gly 97 just after &strand 3 of the ‘known 
structures’. Although this is the more tentative 
part of the sequence’ alignment, this is the only 
region in which a persistent fl prediction precedes 
an absolutely conserved Gly. 
The sequence alignment of table 1 implies that 
the two sections of the ‘oncogene’ polypeptide 
chain will adopt a similar conformation to the cor- 
responding region of the ‘known structures’. Ac- 
cordingly the crystallographic coordinates of 
GPDH [25] were used to model-build the two sec- 
tions of the oncogene v-src. The model building 
was performed using interactive computer graphics 
[26] and involved altering the chemical type of the 
side chains followed by adjustment of side-chain 
torsion angles to obtain allowed stereochemistry. 
The coordinates of GPDH included the bound 
NAD whose chemical structure was altered to ATP 
and the mode of binding of ATP to v-src was in- 
vestigated. Central to this study was the ex- 
perimental evidence [13] from affinity reagents 
which suggests that in CAMP-K the Lys at aligned 
position 32 interacts with the phosphate section of 
ATP. 
3. RESULTS AND DISCUSSION 
The sequenced changes were made from GPDH 
to v-src and it was found that Lys 32 could not 
span the distance to interact with any oxygen atom 
on the phosphate section of ATP when the ATP 
adopted an analogous conformation to the bound 
NAD. In addition the change from an acidic group 
at position 32 of the ‘known structures’ to a Lys in 
the ‘oncogenes’ resulted in the loss of a stabilising 
hydrogen bond with the 2’-hydroxyl of the ribose. 
We concluded that the ATP/‘oncogene’ interac- 
tion would be different from that of the adenosine 
part of NAD with the ‘known structures’ and we 
modelled a possible ATP/‘oncogene’ interaction 
that would include functional roles for the con- 
served residues (see fig.lb and table 2). In this in- 
teraction the N” of Lys 32 forms a salt bridge with 
an oxygen on the &phosphate of ATP. The con- 
served Gly at position 7 ensures the close approach 
of the Nl and C2 atoms of the adenine while a ter- 
minal oxygen of the conserved Asp 95 forms a 
hydrogen bond with the NH2 group at position 6 
of the adenine. The conserved Phe 99 is proposed 
to make hydrophobic interactions with the adenine 
ring. In the model the positively-charged amino 
terminus of the a-helix dipole [27] stabilises the y- 
phosphate group of ATP and this interaction is 
made possible by the presence of the conserved Gly 
389 
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Fig. 1. (A) A stereo diagram of the interaction of NAD and parts of GPDH. The polypeptide backbone and Q3 atoms 
are drawn and the side chain of Asp 32 is shown. The four conserved glycines at positions 7,9, 12 and 97 are labelled 
together with residues 30, 5 and 93 which indicate the strand alignment. The role of the a-helix dipole in interacting 
with the pyrophosphate is denoted by an arrow. (B) A stereo diagram of the proposed ATP-binding site of v-src drawn 
in a similar way to (A). The roles of Gly 7, Gly 9, Gly 12, Gly 97, Lys 32, Asp 95 and Phe 96 together with the a-helix 
dipole (an arrow) in binding ATP are shown. The model was constructed using the program FRODO which was written 
by Dr T.A. Jones [26] and modified for the Evans and Sutherland Picture System 2 and PDP11/60 by Dr I.J. Tickle. 
9 which facilitates the close approach of the y- 
phosphate group. In this model the tyrosine 
residue that is phosphorylated in many of the pro- 
teins is located about 9 residues from the Asp-Phe- 
Gly sequence of the second section. Thus if the 
mechanism involves intrachain autophosphoryla- 
tion, the tyrosine could be spatially close to the y- 
phosphate of the ATP. 
After this model building study was completed, 
our attention was drawn to experimental work on 
the binding of ATP analogous to CAMP-K [14]. 
Our model for the ATP/protein interaction is con- 
sistent with these experimental results. Substitu- 
tion of the NH2 at the 6 position of the adenine by 
a larger group decreased the affinity of the binding 
probably due to steric effects and this was con- 
firmed in the proposed model. Replacement of the 
NH2 at position 6 by oxygen lead to a decrease of 
affinity due to electronic effects which is consistent 
with the proposed hydrogen bond of the adenine 
NH2 with Asp 95. Other studies suggested that the 
glycosidic bond is in the anti conformation rather 
than the syn arrangement and in the model the tor- 
sion angle is 81”, which is the high anti conforma- 
tion. Replacement of either 2 ’ - or the 3 ’ -hydroxyl 
by a hydrogen was not deleterious for binding; this 
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Table 2 
Interactions between v-src and ATP 
October 1984 
Protein atom ATP atom Distance (A> Interaction 
Asp 95 ODl 
Gly 7 CA 
Gly 7 CA 
Phe 96 CD 
Lys 32 NZ 
N6 on adenine 
Nl on adenine 
C2 on adenine 
CS on adenine 
0 on ,& phosphate 
2.8 hydrogen bond 
3.1 van der Waals 
3.0 van der Waals 
3.9 hydrophobic 
3.1 salt bridge 
is consistent with the model in which the ribose 
hydroxyls are exposed to solvent and do not in- 
teract with the protein. The removal of the y- 
phosphate only moderately affected the binding 
while removal of both the ,8- and the y-phosphates 
markedly affected the binding. This is consistent 
with the proposed salt bridge between the ,8- 
phosphate and the Lys 32. 
The proposed model for the ATP binding site of 
v-src would be applicable to all the ‘oncogene’ se- 
quences in table 1 as it is based on the conservation 
of residues. The model should prove helpful in the 
design of experiments to study the binding of ATP 
to these proteins and possibly for the design of in- 
hibitors that might be useful clinical agents. 
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